Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ANIL K SOOD and CHARLOTTE C SUN.
Connection Strength

0.580
  1. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010 Feb 01; 116(3):625-30.
    View in: PubMed
    Score: 0.089
  2. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
    View in: PubMed
    Score: 0.058
  3. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol. 2022 06; 165(3):560-567.
    View in: PubMed
    Score: 0.052
  4. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.050
  5. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 04; 161(1):56-62.
    View in: PubMed
    Score: 0.048
  6. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol. 2020 09; 158(3):653-658.
    View in: PubMed
    Score: 0.046
  7. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020 03; 156(3):715-725.
    View in: PubMed
    Score: 0.044
  8. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol. 2018 Feb; 117(2):236-244.
    View in: PubMed
    Score: 0.037
  9. Unverifiable accomplishments and publications on applications for gynecologic oncology fellowships. Obstet Gynecol. 2012 Mar; 119(3):504-8.
    View in: PubMed
    Score: 0.026
  10. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.
    View in: PubMed
    Score: 0.026
  11. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
    View in: PubMed
    Score: 0.025
  12. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010 Aug; 116(2 Pt 1):269-273.
    View in: PubMed
    Score: 0.023
  13. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
    View in: PubMed
    Score: 0.021
  14. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther. 2006 Sep; 5(9):1136-41.
    View in: PubMed
    Score: 0.018
  15. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.